Characteristics and Treatment of Seizures in Patients with High-Grade Glioma: A Review

Neurosurgery Clinics of North America

Volumn 23, Issue 2, 2012, Pages 227-235

  Englot, Dario J ^a,b   Berger, Mitchel S ^a   Chang, Edward F ^a,b   Garcia, Paul A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anaplastic astrocytoma; Epilepsy; Glioblastoma; High grade glioma; Seizure

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CORTICOSTEROID; DEXAMETHASONE; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; TEMOZOLOMIDE; TOPIRAMATE; VALPROIC ACID;

BALANCE DISORDER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; DISEASE PREDISPOSITION; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EPILEPTIC FOCUS; FOCAL EPILEPSY; GLIOBLASTOMA; GLIOMA; HIRSUTISM; HUMAN; INSOMNIA; LEUKOPENIA; MONOTHERAPY; NAUSEA AND VOMITING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEIZURE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT; WHITE MATTER;

ANTICONVULSANTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; RISK FACTORS; SEIZURES;

EID: 84858601012     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.01.009     Document Type: Review

References (91)

1. Kleihues P., Burger P.C., Scheithauer B.W. The new WHO classification of brain tumours. Brain Pathol 1993, 3:255-268.
2. DeAngelis L.M. Brain tumors. N Engl J Med 2001, 344:114-123.
3. Curran W.J., Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85:704-710.
4. Buckner J.C. Factors influencing survival in high-grade gliomas. Semin Oncol 2003, 30:10-14.
5. Chaichana K.L., Parker S.L., Olivi A., et al. Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg 2009, 111:282-292.
6. Glantz M.J., Cole B.F., Forsyth P.A., et al. Practice parameter: anti-convulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886-1893.
7. Herman S.T. Epilepsy after brain insult: targeting epileptogenesis. Neurology 2002, 59:S21-S26.
8. Moots P.L., Maciunas R.J., Eisert D.R., et al. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995, 52:717-724.
9. Pasquier B., Peoc H.M., Fabre-Bocquentin B., et al. Surgical pathology of drug-resistant partial epilepsy. A 10-year-experience with a series of 327 consecutive resections. Epileptic Disord 2002, 4:99-119.
10. Jacoby A., Wang W., Vu T.D., et al. Meanings of epilepsy in its sociocultural context and implications for stigma: findings from ethnographic studies in local communities in China and Vietnam. Epilepsy Behav 2008, 12:286-297.
11. Sizoo E.M., Braam L., Postma T.J., et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neurol Oncol 2010, 12:1162-1166.
12. van Breemen M.S., Wilms E.B., Vecht C.J. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007, 6:421-430.
13. Sheth R.D. Adolescent issues in epilepsy. J Child Neurol 2002, 17(Suppl 2):2S23-22S27.
14. Jackson J. Localized convulsions from tumors of the brain. Brain 1882, 5:364-374.
15. Englot D.J., Berger M.S., Barbaro N.M., et al. Predictors of seizure-freedom after resection of supratentorial low-grade gliomas. J Neurosurg 2011, 115(2):240-244.
16. Kim O.J., Yong Ahn J., Chung Y.S., et al. Significance of chronic epilepsy in glial tumors and correlation with surgical strategies. J Clin Neurosci 2004, 11:702-705.
17. Lee J.W., Wen P.Y., Hurwitz S., et al. Morphological characteristics of brain tumors causing seizures. Arch Neurol 2010, 67:336-342.
18. Rosati A., Tomassini A., Pollo B., et al. Epilepsy in cerebral glioma: timing of appearance and histological correlations. J Neurooncol 2009, 93:395-400.
19. Pace A., Vidiri A., Galie E., et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003, 14:1722-1726.
20. Liigant A., Haldre S., Oun A., et al. Seizure disorders in patients with brain tumors. Eur Neurol 2001, 45:46-51.
21. Lynam L.M., Lyons M.K., Drazkowski J.F., et al. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg 2007, 109:634-638.
22. Fried I., Kim J.H., Spencer D.D. Limbic and neocortical gliomas associated with intractable seizures: a distinct clinicopathological group. Neurosurgery 1994, 34:815-823. [discussion: 823-4].
23. Penfield W., Erickson T., Tarlov I. Relation of intracranial tumors and symptomatic epilepsy. Arch Neurol Psychiatry 1940, 44:300-315.
24. Lund M. Epilepsy in association with intracranial tumor. Acta Psychiatr Neurol Scand Suppl 1952, 81:1-149.
25. Zaatreh M.M., Firlik K.S., Spencer D.D., et al. Temporal lobe tumoral epilepsy: characteristics and predictors of surgical outcome. Neurology 2003, 61:636-641.
26. Zaatreh M.M., Spencer D.D., Thompson J.L., et al. Frontal lobe tumoral epilepsy: clinical, neurophysiologic features and predictors of surgical outcome. Epilepsia 2002, 43:727-733.
27. Engel J., Bragin A., Staba R., et al. High-frequency oscillations: what is normal and what is not?. Epilepsia 2009, 50:598-604.
28. Delgado-Escueta A.V., Ward A.A., Woodbury D.M., et al. New wave of research in the epilepsies. Adv Neurol 1986, 44:3-55.
29. Fish D.R., Spencer S.S. Clinical correlations: MRI and EEG. Magn Reson Imaging 1995, 13:1113-1117.
30. Spencer S., Huh L. Outcomes of epilepsy surgery in adults and children. Lancet Neurol 2008, 7:525-537.
31. Rossi R., Figus A., Corraine S. Early presentation of de novo high grade glioma with epileptic seizures: electroclinical and neuroimaging findings. Seizure 2010, 19:470-474.
32. Haglund M.M., Berger M.S., Kunkel D.D., et al. Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. J Neurosurg 1992, 77:209-216.
33. Engel J., Van Ness P., Rasmussen T., et al. Outcome with respect to epileptic seizures. Surgical treatment of the epilepsies 1993, 609-621. Raven Press, New York. 2nd edition. J. Engel (Ed.).
34. Ruda R., Trevisan E., Soffietti R. Epilepsy and brain tumors. Curr Opin Oncol 2010, 22:611-620.
35. Shamji M.F., Fric-Shamji E.C., Benoit B.G. Brain tumors and epilepsy: pathophysiology of peritumoral changes. Neurosurg Rev 2009, 32:275-284. [discussion: 284-76].
36. Kim J.H., Guimaraes P.O., Shen M.Y., et al. Hippocampal neuronal density in temporal lobe epilepsy with and without gliomas. Acta Neuropathol 1990, 80:41-45.
37. Rosati A., Marconi S., Pollo B., et al. Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol 2009, 93:319-324.
38. Bordey A., Sontheimer H. Properties of human glial cells associated with epileptic seizure foci. Epilepsy Res 1998, 32:286-303.
39. Eid T., Thomas M.J., Spencer D.D., et al. Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy. Lancet 2004, 363:28-37.
40. Laming P.R., Cosby S.L., O'Neill J.K. Seizures in the Mongolian gerbil are related to a deficiency in cerebral glutamine synthetase. Comp Biochem Physiol C 1989, 94:399-404.
41. Chang E.F., Potts M.B., Keles G.E., et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008, 108:227-235.
42. Awad I.A., Rosenfeld J., Ahl J., et al. Intractable epilepsy and structural lesions of the brain: mapping, resection strategies, and seizure outcome. Epilepsia 1991, 32:179-186.
43. Sanai N., Berger M.S. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008, 62:753-764. [discussion: 264-6].
44. Sanai N., Polley M.Y., McDermott M.W., et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011, 115(1):3-8.
45. Chalifoux R., Elisevich K. Effect of ionizing radiation on partial seizures attributable to malignant cerebral tumors. Stereotact Funct Neurosurg 1996, 67:169-182.
46. Rogers L.R., Morris H.H., Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology 1993, 43:1599-1601.
47. Sherman J.H., Moldovan K., Yeoh H.K., et al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 2011, 114(6):1617-1621.
48. Vecht C.J., Wilms E.B. Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther 2010, 10:663-669.
49. Merrell R.T., Anderson S.K., Meyer F.B., et al. Seizures in patients with glioma treated with phenytoin and levetiracetam. J Neurosurg 2010, 113:1176-1181.
50. van Breemen M.S., Rijsman R.M., Taphoorn M.J., et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 2009, 256:1519-1526.
51. Su J.M., Li X.N., Thompson P., et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res 2011, 17:589-597.
52. Rosati A., Buttolo L., Stefini R., et al. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol 2010, 67:343-346.
53. Usery J.B., Michael L.M., Sills A.K., et al. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol 2010, 99:251-260.
54. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002, 16:669-694.
55. Kerrigan S., Grant R. Anti-epileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst Rev 2011, 8. CD008586.
56. Lim D.A., Tarapore P., Chang E., et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol 2009, 93:349-354.
57. Newton H.B., Goldlust S.A., Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 2006, 78:99-102.
58. Marks W.J., Garcia P.A. Management of seizures and epilepsy. Am Fam Physician 1998, 57:1589-1600. 1603-4.
59. Cramer J.A., Mintzer S., Wheless J., et al. Adverse effects of anti-epileptic drugs: a brief overview of important issues. Expert Rev Neurother 2010, 10:885-891.
60. Cascino G.D. When drugs and surgery don't work. Epilepsia 2008, 49(Suppl 9):79-84.
61. Sisodiya S.M., Lin W.R., Harding B.N., et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002, 125:22-31.
62. Taphoorn M.J., Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol 2004, 3:159-168.
63. Wagner G.L., Wilms E.B., Van Donselaar C.A., et al. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 2003, 12:585-586.
64. Batchelor T.T., Byrne T.N. Supportive care of brain tumor patients. Hematol Oncol Clin North Am 2006, 20:1337-1361.
65. Baker G.A., Jacoby A., Buck D., et al. Quality of life of people with epilepsy: a European study. Epilepsia 1997, 38:353-362.
66. Auriel E., Landov H., Blatt I., et al. Quality of life in seizure-free patients with epilepsy on monotherapy. Epilepsy Behav 2009, 14:130-133.
67. Lloyd A., McIntosh E., Price M. The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment. Pharmacoeconomics 2005, 23:1167-1181.
68. Blackburn S.C., Oliart A.D., Garcia Rodriguez L.A., et al. Anti-epileptics and blood dyscrasias: a cohort study. Pharmacotherapy 1998, 18:1277-1283.
69. Tohen M., Castillo J., Baldessarini R.J., et al. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 1995, 152:413-418.
70. Brown P.D., Krishnan S., Sarkaria J.N., et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008, 26:5603-5609.
71. Drappatz J., Schiff D., Kesari S., et al. Medical management of brain tumor patients. Neurol Clin 2007, 25:1035-1071. ix.
72. Galanis E., Jaeckle K.A., Maurer M.J., et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009, 27:2052-2058.
73. Raymond E., Brandes A.A., Dittrich C., et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008, 26:4659-4665.
74. Michelucci R. Optimizing therapy of seizures in neurosurgery. Neurology 2006, 67:S14-S18.
75. Pursche S., Schleyer E., von Bonin M., et al. Influence of enzyme-inducing anti-epileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 2008, 3:198-203.
76. Bobustuc G.C., Baker C.H., Limaye A., et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 2010, 12:917-927.
77. Jaeckle K.A., Ballman K., Furth A., et al. Correlation of enzyme-inducing anti-convulsant use with outcome of patients with glioblastoma. Neurology 2009, 73:1207-1213.
78. North J.B., Penhall R.K., Hanieh A., et al. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg 1983, 58:672-677.
79. Franceschetti S., Binelli S., Casazza M., et al. Influence of surgery and anti-epileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir (Wien) 1990, 103:47-51.
80. Forsyth P.A., Weaver S., Fulton D., et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003, 30:106-112.
81. Glantz M.J., Cole B.F., Friedberg M.H., et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996, 46:985-991.
82. Sirven J.I., Wingerchuk D.M., Drazkowski J.F., et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004, 79:1489-1494.
83. Matthew E., Sherwin A.L., Welner S.A., et al. Seizures following intracranial surgery: incidence in the first post-operative week. Can J Neurol Sci 1980, 7:285-290.
84. Kuijlen J.M., Teernstra O.P., Kessels A.G., et al. Effectiveness of anti-epileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure 1996, 5:291-298.
85. Lee S.T., Lui T.N., Chang C.N., et al. Prophylactic anti-convulsants for prevention of immediate and early postcraniotomy seizures. Surg Neurol 1989, 31:361-364.
86. Kvam D.A., Loftus C.M., Copeland B., et al. Seizures during the immediate postoperative period. Neurosurgery 1983, 12:14-17.
87. Telfeian A.E., Philips M.F., Crino P.B., et al. Postoperative epilepsy in patients undergoing craniotomy for glioblastoma multiforme. J Exp Clin Cancer Res 2001, 20:5-10.
88. De Santis A., Villani R., Sinisi M., et al. Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia 2002, 43:175-182.
89. Lwu S., Hamilton M.G., Forsyth P.A., et al. Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience. J Neurooncol 2010, 96:403-408.
90. Riva M., Salmaggi A., Marchioni E., et al. Tumour-associated epilepsy: clinical impact and the role of referring centres in a cohort of glioblastoma patients. A multicentre study from the Lombardia Neurooncology Group. Neurol Sci 2006, 27:345-351.
91. Siomin V., Angelov L., Li L., et al. Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. J Neurooncol 2005, 74:211-215.